Maintenance Therapy With Brentuximab Vedotin (SGN-35) After Allogeneic Hematopoietic Cell Transplantation for Hodgkin Lymphoma and CD30+ Hematologic Malignancies

Trial Profile

Maintenance Therapy With Brentuximab Vedotin (SGN-35) After Allogeneic Hematopoietic Cell Transplantation for Hodgkin Lymphoma and CD30+ Hematologic Malignancies

Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 11 Jun 2014

At a glance

  • Drugs Brentuximab vedotin (Primary)
  • Indications Haematological malignancies; Hodgkin's disease
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 18 Apr 2014 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 18 Jun 2013 Seattle Genetics added as trial associations and lead trial centre as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top